Brittany S. Bruggeman, MD, reviews teplizumab (Tzield), islet autoantibody screening, and automated insulin delivery, and how pediatricians can help families.

Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.

ISPAD, EASD, and ADA urge pediatric diabetes teams to build center-specific transition policies, use readiness checklists, and ensure timely handoffs to adult clinicians.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.

Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.

Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.

At AAP 2026, Justin Wheeler, MD, discussed bowel cleanouts, maintenance therapy, and behavioral strategies for managing constipation in children.